Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

被引:259
作者
Powles, T
Paterson, S
Kanis, JA
McCloskey, E
Ashley, S
Tidy, A
Rosenqvist, K
Smith, I
Ottestad, L
Legault, S
Pajunen, M
Nevantaus, A
Männistö, E
Suovuori, A
Atula, S
Nevalainen, J
Pylkkänen, L
机构
[1] Royal Marsden Natl Hlth Serv Trust, London, England
[2] Univ Sheffield, Sheffield, S Yorkshire, England
[3] Univ Calgary, Calgary, AB, Canada
[4] Tom Baker Canc Clin, Calgary, AB, Canada
[5] Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada
[6] Cent Hosp Jyvaskyla, Jyvaskyla, Finland
[7] Norwegian Radium Hosp, Oslo, Norway
关键词
D O I
10.1200/JCO.2002.11.080
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The development of bone metastases depends on tumor-induced osteoclastic resorption of bone, which may be inhibited by the antiosteolytic bisphosphonate clodronate. Given to patients with primary breast cancer, clodronate might reduce the subsequent incidence of bone metastases. Patients and Methods: This double-blind, multicenter trial accrued 1,069 assessable patients with operable breast cancer between 1989 and 1995. All patients received surgery, radiotherapy, chemotherapy, and tamoxifen as required. Patients were randomized to receive oral clodronate 1,600 mg/d or a placebo for 2 years starting within 6 months of primary treatment. The primary end point was relapse in bone, analyzed on an intent-to-treat basis, during the medication period and during the total follow-up period (median follow-up, 2,007 days). Secondary end points were relapse in other sites, mortality, and toxicity. Results: During the total follow-up period, there was a nonsignificant reduction in occurrence of bone metastases (clodronate, n = 63; placebo, n = 80; hazards ratio [HR], 0.77; 95% confidence interval [Cl], 0.56 to 1.08; P =. 127). During the medication period there was a significant reduction in the occurrence of bone metastases (clodronate, n = 12; placebo, n = 28; HR, 0.44; 95% Cl, 0.22 to 0.86; P = .016). The occurrence of non-osseous metastases was similar (clodronate, n = 112; placebo, n = 128; P = .257), but there was a significant reduction in mortality (clodronate, n = 98; placebo, n 129; P = .047) during the total follow-up period. Conclusion: Clodronate, given to patients with primary operable breast cancer, may reduce the occurrence of bone metastases, although this reduction was only significant during this medication period. There was a significant reduction in mortality. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:3219 / 3224
页数:6
相关论文
共 13 条
  • [1] Reduction in new metastases in breast cancer with adjuvant clodronate treatment
    Diel, IJ
    Solomayer, EF
    Costa, SD
    Gollan, C
    Goerner, R
    Wallwiener, D
    Kaufmann, M
    Bastert, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (06) : 357 - 363
  • [2] Bisphosphonates in the prevention of bone metastases: Current evidence
    Diel, IJ
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (04) : 75 - 80
  • [3] ELOMAA I, 1983, LANCET, V1, P146
  • [4] BISPHOSPHONATES - PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOR-INDUCED HYPERCALCEMIC AND METASTATIC BONE-DISEASE
    FLEISCH, H
    [J]. DRUGS, 1991, 42 (06) : 919 - 944
  • [5] MECHANISMS OF BONE DESTRUCTION IN DEVELOPMENT OF SKELETAL METASTASES
    GALASKO, CSB
    [J]. NATURE, 1976, 263 (5577) : 507 - 508
  • [6] Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
    Hortobagyi, GN
    Theriault, RL
    Porter, L
    Blayney, D
    Lipton, A
    Sinoff, C
    Wheeler, H
    Simeone, JF
    Seaman, J
    Knight, RD
    Heffernan, M
    Reitsma, DJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (24) : 1785 - 1791
  • [7] Clodronate decreases the frequency of skeletal metastases in women with breast cancer
    Kanis, JA
    Powles, T
    Paterson, AHG
    McCloskey, EV
    Ashley, S
    [J]. BONE, 1996, 19 (06) : 663 - 667
  • [8] Bisphosphonates as anticancer drugs
    Mundy, GR
    Yoneda, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (06) : 398 - 400
  • [9] DOUBLE-BLIND CONTROLLED TRIAL OF ORAL CLODRONATE IN PATIENTS WITH BONE METASTASES FROM BREAST-CANCER
    PATERSON, AHG
    POWLES, TJ
    KANIS, JA
    MCCLOSKEY, E
    HANSON, J
    ASHLEY, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) : 59 - 65
  • [10] Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer
    Powles, TJ
    McCloskey, E
    Paterson, AHG
    Ashley, S
    Tidy, VA
    Nevantaus, A
    Rosenqvist, K
    Kanis, J
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) : 704 - 708